Multiple sclerosis and related disordersHumansNeuromyelitis OpticaRituximabLymphocyte CountImmunologic Factors
Rituximab regimens and lymphocyte counts in patients with neuromyelitis optica: A systematic review.
Paola Andrea Ortiz-Salas, Maria Alejandra Quilaguy-Jimenez, Juan Sebastian Castañeda, Natalia Gómez-Salazar, Eliana Pineda-Mateus
Published: 202510.1016/j.msard.2025.106798
Abstract
OBJECTIVE: To evaluate the utility of peripheral blood B-cell counts, specifically CD19+ and CD27+ lymphocytes by flow cytometry, in patients with neuromyelitis optica (NMO) treated with rituximab. METHODS: A systematic review was conducted following…
Preview only. Read the full abstract at the source